So far, ten anti-COVID-19 virus vaccines have been authorised for use in various parts of the world
The Corona virus that has caused the current pandemic is called SARS-CoV-2, or Severe Acute Respiratory Syndrome Corona Virus-2. The disease itself is called COVID-19, or Corona Virus Disease, 2019. So far, ten anti-COVID-19 virus vaccines have been authorised for use in various parts of the world. Eighty one vaccines are undergoing trials with twenty at advanced stages.
The first one to arrive in Pakistan is a Chinese vaccine made by the state owned Chinese company, Sinopharm. It was developed by the Beijing Institute of Biological Products. It is a whole virus, killed vaccine and has been given an ‘emergency use authorisation’ by the Drug Regulatory Authority of Pakistan (DRAP). The results of the large scale clinical trials, called Phase III trials have not been published yet in peer reviewed medical journals. The trials have taken place in various countries, including UAE an
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 .
Vaccitech LimitedFebruary 1, 2021 GMT
OXFORD, United Kingdom, Feb. 01, 2021 (GLOBE NEWSWIRE) Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with chronic hepatitis B (CHB) infection. The study plans to enroll 64 patients in South Korea, Taiwan and the UK.